{"id":"platinum-based-dual-agent-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Platinum agents (such as cisplatin, carboplatin, or oxaliplatin) form covalent adducts with DNA, causing interstrand and intrastrand crosslinks that prevent DNA replication and transcription. When combined as a dual-agent regimen, the two components may target different pathways or enhance each other's cytotoxic effects, potentially overcoming resistance mechanisms and improving efficacy in solid tumors.","oneSentence":"Platinum-based dual-agent chemotherapy uses two platinum compounds or a platinum compound combined with another cytotoxic agent to create synergistic DNA damage and cell death in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:20.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication pending phase 3 trial results)"}]},"trialDetails":[{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT07131319","phase":"PHASE2, PHASE3","title":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-04-21","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06930794","phase":"PHASE3","title":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","status":"RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2025-07-07","conditions":"Non-Small Cell Lung Cancer","enrollment":300},{"nctId":"NCT06121505","phase":"PHASE2","title":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-03-01","conditions":"Lung Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT07215962","phase":"","title":"Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-11-22","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":300},{"nctId":"NCT07198217","phase":"PHASE2","title":"Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient","status":"RECRUITING","sponsor":"Zibo Municipal Hospital","startDate":"2021-05-25","conditions":"NSCLC, Tislelizumab, Chemotherapy","enrollment":20},{"nctId":"NCT07083375","phase":"PHASE2","title":"A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-08-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT03800134","phase":"PHASE3","title":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-06","conditions":"Non-Small Cell Lung Cancer","enrollment":825},{"nctId":"NCT06598527","phase":"PHASE3","title":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study","status":"RECRUITING","sponsor":"Yang Hong","startDate":"2024-10-15","conditions":"Lung Cancer (NSCLC)","enrollment":360},{"nctId":"NCT06944470","phase":"PHASE2","title":"JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-04-20","conditions":"NSCLC","enrollment":76},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT06863831","phase":"NA","title":"A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-22","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":536},{"nctId":"NCT06686381","phase":"PHASE2","title":"Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W","status":"NOT_YET_RECRUITING","sponsor":"American University of Beirut Medical Center","startDate":"2025-04-15","conditions":"Muscle-invasive Bladder Cancer","enrollment":80},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT04144608","phase":"PHASE2","title":"Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC","status":"COMPLETED","sponsor":"Yongchang Zhang","startDate":"2020-01-16","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04158440","phase":"PHASE3","title":"Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-04-07","conditions":"Stage II-III Non-small Cell Lung Cancer","enrollment":501},{"nctId":"NCT04622007","phase":"PHASE2","title":"Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Effector Therapeutics","startDate":"2021-06-02","conditions":"Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT06276933","phase":"PHASE4","title":"A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Tongji University","startDate":"2024-02-22","conditions":"Lung Cancer, Camrelizumab","enrollment":104},{"nctId":"NCT02915523","phase":"PHASE1, PHASE2","title":"Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2016-12-19","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":140},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT05791097","phase":"PHASE3","title":"Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT01257139","phase":"PHASE3","title":"Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a \"Classical\" Strategy of Treatment Allocation, With an\"Optimized\" Strategy Allocating the Same Treatments","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2010-01","conditions":"Non Small-cell Lung Cancer","enrollment":490},{"nctId":"NCT04229615","phase":"PHASE3","title":"A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-06-02","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":690},{"nctId":"NCT03520231","phase":"PHASE2","title":"Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-09-04","conditions":"Urothelial Carcinoma, Kidney Cancer, Ureter Cancer","enrollment":6},{"nctId":"NCT04316364","phase":"PHASE3","title":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-14","conditions":"Non-Small-Cell Lung Cancer","enrollment":537},{"nctId":"NCT04943029","phase":"PHASE2","title":"Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-08-20","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04772287","phase":"PHASE3","title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-03-31","conditions":"Non Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT03986528","phase":"PHASE4","title":"Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Jie Li","startDate":"2019-08-28","conditions":"NSCLC","enrollment":334},{"nctId":"NCT01675765","phase":"PHASE1","title":"Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"Aduro Biotech, Inc.","startDate":"2014-09-03","conditions":"Malignant Pleural Mesothelioma","enrollment":60},{"nctId":"NCT02162914","phase":"PHASE2","title":"Regorafenib Versus Placebo to Treat Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Erasme University Hospital","startDate":"2014-03-14","conditions":"Cholangiocarcinoma","enrollment":66},{"nctId":"NCT03758677","phase":"PHASE2","title":"Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2020-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04181372","phase":"PHASE2","title":"A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2019-12","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":50},{"nctId":"NCT01856101","phase":"PHASE2","title":"Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2013-02","conditions":"Carcinoma Transitional Cell","enrollment":22},{"nctId":"NCT03672136","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2018-11-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":25},{"nctId":"NCT03411967","phase":"PHASE2","title":"Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC","status":"UNKNOWN","sponsor":"Zigong No.1 Peoples Hospital","startDate":"2018-02-01","conditions":"Lung Cancer","enrollment":20},{"nctId":"NCT01648517","phase":"PHASE2","title":"Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-07-27","conditions":"Non-small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT01523457","phase":"PHASE2","title":"Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-10","conditions":"Metastatic Pancreatic Cancer, Pancreatic Cancer","enrollment":75},{"nctId":"NCT01328951","phase":"PHASE3","title":"A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":643},{"nctId":"NCT02392676","phase":"PHASE3","title":"Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2016-07","conditions":"Platinum Sensitive Relapsed Ovarian Cancer","enrollment":""},{"nctId":"NCT00424255","phase":"PHASE3","title":"Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12","conditions":"Neoplasms, Head and Neck","enrollment":688}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"platinum-based dual-agent chemotherapy","genericName":"platinum-based dual-agent chemotherapy","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Platinum-based dual-agent chemotherapy uses two platinum compounds or a platinum compound combined with another cytotoxic agent to create synergistic DNA damage and cell death in cancer cells. Used for Advanced or metastatic solid tumors (specific indication pending phase 3 trial results).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}